Pfizer’s Oporia Is “Not Approvable” For Osteoporosis Prevention
This article was originally published in The Pink Sheet Daily
Executive Summary
The company says it will consider “various possible courses of action” following FDA’s decision on the selective estrogen receptor modulator.